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Abstract
Family planning is essential for any comprehensive treatment plan for women of reproductive age 
with multiple sclerosis (MS), including counseling on using effective contraception to optimally 
time desired and prevent unintended pregnancies. This topical review summarizes the first 
evidence-based recommendations on contraception safety for women with MS. In 2016, evidence-
based recommendations for contraceptive use by women with MS were included in US Medical 
Eligibility Criteria for Contraceptive Use. They were developed after review of published scientific 
evidence on contraception safety and consultation with experts. We summarize and expand on the 
main conclusions of the Centers for Disease Control and Prevention guidance. Most contraceptive 
methods appear based on current evidence to be safe for women with MS. The only restriction is 
use of combined hormonal contraceptives among women with MS with prolonged immobility 
because of concerns about possible venous thromboembolism. Disease-modifying therapies 
(DMTs) do not appear to decrease the effectiveness of hormonal contraception although formal 
drug–drug interaction studies are limited. Neurologists can help women with MS make 
contraceptive choices that factor their level of disability, immobility, and medication use. For 
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women with MS taking potentially teratogenic medications, highly effective methods that are 
long-acting (e.g. intrauterine devices, implants) might be the best option.
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Introduction
Contraception is an important consideration for women with multiple sclerosis (MS). MS is 
more prevalent among females, and the peak age of onset for women is during the 
childbearing years.1,2 MS does not seem to significantly impair fertility although there is 
emerging data on decreased ovarian reserve and higher prevalence of thyroid autoimmunity 
in MS patients, possibly affecting fertility.2–5 A chronic neurologic illness may also 
influence pregnancy intentions. Although some patients report having completed their 
families prior to MS diagnosis, one study found that among women with MS who did not 
become pregnant after diagnosis, nearly one-third cited MS-related concerns such as 
symptoms interfering with parenting, burdening their partner, and children inheriting MS.6 
Many women with MS use disease modifying therapies (DMTs). DMTs are generally not 
recommended for women trying to become pregnant and there are known risks to the fetus 
associated with some treatments, and none are specifically approved for use in pregnancy.7 
If a woman is on certain DMTs, a washout period before conception is recommended.2 
Table 1 summarizes the DMTs in wide use today with known or suspected pregnancy risks. 
Providers are always encouraged to review up-to-date product-specific information for their 
practice location and scope, prior to giving advice to their patients.
The optimal time for a woman with MS to conceive should be considered individually, based 
on the activity of her disease, her response to treatment, and the availability of resources to 
manage the challenges of early motherhood. As such, family planning should be an essential 
part of any comprehensive treatment plan for women of reproductive age with MS, including 
regular counseling on the use of effective contraception to optimally time desired 
pregnancies and prevent unintended pregnancies. However, neurologists may not be well 
equipped to discuss contraception with patients. A survey of female neurologists from the 
United States and Canada found that most referred their patients to an obstetrician–
gynecologist or internist for contraceptive counseling, and many were unsure whether their 
MS patients used contraception or the type of method used.14
Many methods of contraception are available to women and couples. When choosing an 
appropriate contraceptive method, factors to consider include safety, availability, 
acceptability, and effectiveness. For women with MS, additional issues may include 
difficulty swallowing pills or manual dexterity needed for placing vaginal rings and barrier 
methods. The effectiveness of a contraceptive method depends on the inherent effectiveness 
of the method itself and on how consistency and correctly the method is used (Figure 1).15 
Whereas pregnancy rates during perfect use show how effective a method is in a 
hypothetical “perfect use” scenario, pregnancy rates during typical use show how effective a 
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method is during actual use, including inconsistent and/or incorrect use.16 The most 
effective reversible methods of contraception during typical use are intrauterine devices 
(IUDs) and implants, collectively known as long-acting, reversible contraception (LARC). 
LARC methods are highly effective because once in place, they do not require regular user 
compliance. LARC methods provide pregnancy protection for 3–10 years depending on the 
device but can be removed at any time if the woman chooses to become pregnant (or for any 
other reason). Methods that are user-dependent, such as oral contraceptive pills and 
condoms, rely on consistent and correct use and, as a result, are less effective during typical 
use. When counseling women about contraceptive options, the full range and effectiveness 
of methods for which they are medically eligible should be discussed.
Although several clinical reviews are available on the management of and therapeutic 
considerations for women with MS during the reproductive years,2,7,17,18 the focus of these 
reviews has largely been on issues around the time pregnancy. Topics have included the 
effect of pregnancy on the MS disease course; the management of MS during pregnancy, 
labor, and postpartum; and safety of breastfeeding while on DMTs. Safe and effective 
contraceptive choices for women with MS have not been included. This topical review will 
specifically focus on the safety of contraception being used for contraceptive purposes for 
women with MS; it does not consider the safety of contraception as primary or adjunct MS 
therapy.
Contraception guidance for healthcare providers
The US Centers for Disease Control and Prevention (CDC) publishes the US Medical 
Eligibility Criteria for Contraceptive Use15 (US MEC), adapted from the World Health 
Organization Medical Eligibility Criteria for Contraceptive Use19 (WHO MEC), which 
provides evidence-based guidance on the safety of contraceptive methods for women with 
certain characteristics or medical conditions. The recommendations refer to contraceptive 
methods being used for contraceptive purposes and do not consider the use of contraceptive 
methods for treatment of medical conditions because the eligibility criteria in these 
situations might be different. The goal of the recommendations is to remove unnecessary 
medical barriers to accessing and using contraception, thus reducing unintended 
pregnancies. They are intended to be a source of clinical guidance assisting healthcare 
providers when they counsel women, men, and couples about family planning. Although 
adapted from the WHO MEC to be specific to the US context (e.g. addition of 
recommendations for new medical conditions), the recommendations in the US MEC are 
based on rigorous identification and critical appraisal of the scientific evidence and input 
from experts, and can reasonably be applied in other settings.
For each medical condition and personal characteristic included in the US MEC, eligibility 
categories have been assigned assessing the safety of the specific contraceptive method for 
women with the specific medical condition or personal characteristic:15
• Category 1 comprises conditions for which no restrictions exist for use of the 
contraceptive method.
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• Category 2 comprises conditions for which the contraceptive method generally 
can be used although careful follow-up might be required.
• Category 3 comprises conditions for which use of the contraceptive method 
usually is not recommended unless other more appropriate contraceptive 
methods are not available or acceptable. The severity of the condition and the 
availability, practicality, and acceptability of alternative contraceptive methods 
should be considered, and careful follow-up is required. Hence, provision of a 
contraceptive method to a woman with a condition classified as category 3 
requires careful clinical judgment and access to clinical services.
• Category 4 comprises conditions that represent an unacceptable health risk if the 
contraceptive method is used.
The US MEC was first published in 2010, but did not include recommendations for 
contraceptive use by women with MS. The WHO MEC also does not include 
recommendations for contraceptive use by women with MS.
Updating the contraception guidance to include MS
As part of a process to update the US MEC, the CDC held a meeting with family planning 
experts and representatives from partner organizations to solicit input on the scope and 
process for updating the US MEC. Based on CDC receipt of feedback from healthcare 
providers via email and questions received at conferences about contraception for women 
with MS, MS was identified as a new medical condition to add.
A systematic review was conducted to evaluate the evidence on the safety of contraceptive 
use among women with MS.20 The PubMed database was searched for peer-reviewed 
articles published in any language from database inception through July 2015. The review 
included studies that examined health outcomes among women diagnosed with MS initiating 
or continuing a contraceptive method, but excluded studies that evaluated the risk of 
developing MS among women using contraception. Prior to conducting the review, potential 
safety concerns were identified in consultation with MS experts. These included possible 
worsening of disease through relapse or disease progression with hormonal method use; 
compounded risk for venous thromboembolism (VTE) with hormonal method use among 
MS patients with increased risk for VTE due to immobility and comprised bone health with 
use of progestin-only injectables (depot medroxyprogesterone acetate (DMPA)). Potential 
logistical concerns related to contraceptive use among women with MS were also identified 
during scoping discussions. These included potential difficulty with placement of IUDs, 
vaginal rings, and diaphragms in women with vaginal stenosis, and potential difficultly with 
patient placement of vaginal rings and diaphragms for women with impaired fine motor 
control in the hands or significant spasticity in the legs.
The systematic review identified 111 articles, of which four studies met our inclusion 
criteria: one randomized controlled trial (Italy),21 two retrospective cohort studies (Italy and 
Portugal),22,23 and one cross-sectional study (Germany).24 Although the body of evidence 
was limited in quantity and quality of studies, the review concluded that the use of combined 
oral contraceptives or oral contraceptives (type not specified) does not worsen the clinical 
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course of MS, defined as disability level, disease severity or progression, relapse, or number 
of new brain lesions on magnetic resonance imaging after 96 weeks of follow-up. No studies 
were identified that examined the safety of other contraceptive methods, and no studies were 
identified that examined other safety outcomes (e.g. VTE or changes in bone mineral 
density). Research gaps were identified including the need for additional studies with strong 
designs that examine a broader range of contraceptive methods and outcomes, report the 
timing of contraceptive use relative to outcome measurement, and include women with 
different types of MS. The evidence was presented to a national panel of experts invited to 
provide their individual perspectives on the scientific evidence presented and potential 
recommendations. After the meeting, CDC developed the recommendations taking into 
consideration the perspectives provided during the meeting; further details on the process are 
described elsewhere.15
Recommendations for women with MS
The US MEC 201615 includes recommendations for contraceptive use by women with MS 
(Table 2).
IUDs—IUDs include the copper-containing IUD (Cu-IUD) and the levonorgestrel-releasing 
IUD (LNG-IUD). For both the Cu-IUD and the LNG-IUD, there are no restrictions for use 
by women with MS (Category 1).
Progestin-only contraceptives—Progestin-only contraceptives include etonogestrel 
implants, DMPA, and progestin-only pills (POPs). For implants and POPs, there are no 
restrictions for use by women with MS (Category 1). For DMPA, women with MS can 
generally use the method although careful follow-up might be required (Category 2) related 
to concerns about bone health. Women with MS might have compromised bone health from 
disease-related disability, immobility, or use of corticosteroids,20 and use of DMPA has been 
associated with small changes in bone mineral density.25
Combined hormonal contraceptives—Combined hormonal contraceptives (CHCs) 
include low-dose combined oral contraceptives (containing ≤35 μg ethinyl estradiol), the 
hormonal patch, and the vaginal ring. Classifications for CHCs for women with MS differ 
based on immobility status. For women with MS without prolonged immobility, there are no 
restrictions for use of CHCs (Category 1). However, for women with MS with prolonged 
immobility, CHCs are usually not recommended unless other more appropriate contraceptive 
methods are not available or acceptable (Category 3). This is because of inferred concerns 
about VTE risk. Although no evidence was found examining the effect of CHCs on VTE 
among women with MS, women with MS are at higher risk than unaffected women for 
VTE,26,27 and CHCs increase VTE risk.28
Barrier methods—Barrier methods include condoms (male and female), spermicides, and 
diaphragm with spermicide or cervical cap. For these methods, there are no restrictions for 
use by women with MS (Category 1).
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Other methods—Other methods of contraception are included in the US MEC 2016 
including fertility awareness-based methods, the lactational amenorrhea method, coitus 
interruptus (withdrawal), and female and male sterilization. None of these methods are 
restricted for women with MS.
Although a specific contraceptive method may be classified as a Category 1 (which means 
that the method can be used with no restrictions related to safety), it does not necessarily 
mean that the method is the best choice for the patient. When counseling women of 
reproductive age with MS about contraception, providers, including neurologists, should 
always consider the individual social, cultural, and clinical circumstances of the patient 
seeking advice. For example, for a woman with MS taking potentially feto-toxic DMTs, 
more effective methods such as LARC might be the best option to avoid unintended 
pregnancy or delay pregnancy until teratogenic medications are no longer needed.
Drug interaction considerations
DMTs that were approved by the US Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA) for treatment of relapsing forms of MS prior to July 
2015 were considered as related to drug interactions with contraception. Alemtuzumab, 
approved in the United States in 2014, was the most recently approved DMT considered. 
DMTs do not appear to decrease the effectiveness of hormonal contraception although 
formal drug–drug interaction studies are limited.29 However, all medications should be 
reviewed at every visit, as some therapies taken for MS symptom management may affect 
contraceptive efficacy. A number of medications used for management of specific MS 
symptoms and other common illness may have interactions with OCPs. These interactions 
may result in either decreased efficacy of oral contraceptives or a change in efficacy of the 
other medications. One notable example is modafinil, commonly used (off label) to treat MS 
fatigue.2 Oral modafinil has been shown to decrease the level of ethinyl estradiol by altering 
drug metabolism through the cytochrome P450-mediated oxidative pathways.30,31 Thus, 
efficacy of oral contraceptives may be reduced in MS patients taking modafinil, potentially 
leading to unintended pregnancy. Another example is anticonvulsant therapy. Certain 
anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone, topiramate, and 
oxcarbazepine) lower the effectiveness of progestin-only contraception and CHCs.15 Women 
who are long-term users of these drugs should be encouraged to use another contraceptive 
method. Lamotrigine does not appear to affect the efficacy of progestin-only contraception, 
but pharmacokinetic studies have shown that levels of lamotrigine decrease significantly 
during the use of combined oral contraceptives.15 The US MEC includes recommendations 
for contraceptive use for select drug interactions.
Other contraception guidance and available healthcare provider tools
The CDC also publishes the US Selected Practice Recommendations for Contraceptive 
Use32 (US SPR), adapted from the WHO Selected Practice Recommendations for 
Contraceptive Use33 (WHO SPR), a companion document to the US MEC that addresses a 
select group of common, yet complex, issues regarding initiation and use of specific 
contraceptive methods. The US SPR includes topics such as how to be reasonably certain 
that a woman is not pregnant, when to start using specific contraceptive methods, 
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examinations and tests needed before initiation of contraceptive methods, routine follow-up 
after contraceptive initiation, and management of women with bleeding irregularities while 
using contraception. The US SPR also includes recommended actions for women in the 
event of late DMPA reinjections, late or missed doses of CHCs, and missed POPs. While it 
is less likely that MS neurologists will be routinely handling contraceptive management 
issues such as side effects, the general awareness of these resources can be very helpful.
Additionally, CDC, in collaboration with the US Office of Population Affairs, publishes 
Providing Quality Family Planning Services34 (QFP). The QFP provides recommendations 
on how to provide family planning services so that individuals can achieve their desired 
number and spacing of children, increase the chance that a baby will be born healthy, and 
improve their health even if they choose to not have children. The QFP is intended for all 
current or potential providers of family planning services and includes topics such as 
providing contraceptive counseling, helping clients achieve pregnancy, basic infertility 
services, preconception health services, and sexually transmitted disease services.
In an effort to disseminate and promote use of the US MEC, US SPR, and QFP, several 
provider tools have been developed and are available on CDC’s Division of Reproductive 
Health website at no cost for download or order (Table 3). Although these guidance 
documents and provider tools were developed to assist US healthcare providers, the 
recommendations and tools can reasonably be used in other countries in the absence of 
locally adapted guidance.
Conclusion
Contraception is important for women of reproductive age with MS to optimally time 
desired pregnancies and prevent unintended pregnancies. In 2016, the US MEC published 
evidence-based recommendations for contraceptive use by women with MS to assist health-
care providers, including neurologists, when counseling women about contraception. Most 
methods of contraception appear to be safe for women with MS based on current evidence—
the only exception is use of CHCs by women with MS with prolonged immobility due to 
concerns about possible VTE risk. Although neurologists may frequently refer MS patients 
to other providers for contraceptive care, neurologists can play a key role in promoting 
reproductive health by routinely assessing their patients’ pregnancy intentions and helping 
women make contraceptive choices that factor in their level of disability, immobility, and 
medication use. When counseling women with MS about contraception, the full range of 
methods for which they are medically eligible should be discussed in order for women to 
choose the best method for their personal circumstances. For women with MS taking 
potentially teratogenic medications, highly effective methods that are long-acting, such as 
IUDs and implants, might be the best option to avoid unintended pregnancy.
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Figure 1. 
Effectiveness of family planning methods.
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Table 1
FDA- and EMA-approved disease-modifying therapies in wide use today, with known or suspected pregnancy 
risksa.8–13
Name Teratogenic in animal models Signal for increased malformations in 
human pregnancies
Recommended washout period before 
conception attempt
Fingolimod Yes Yes 2 months
Dimethyl fumarate Yes No None
Teriflunomide Yes Yes in precursor leflunomide Until plasma levels are below 0.02 
μg/mL
Alemtuzumab No (decreased embryonic 
survival observed in some 
species)
No 4 months
Natalizumab No (decreased embryonic 
survival observed in some 
species)
Nob (transient hematologic 
abnormalities in exposed newborns 
observed)
1–2 menstrual cycles unless concern for 
disease reactivation in pregnancy
Daclizumab No None in clinical development programs 4 months
FDA: Food and Drug Administration; EMA: European Medicines Agency.
a
Extensive body of published literature does not support any increased pregnancy risks with the glatiramer acetate and interferons. Off-label 
treatments or treatments not in wide clinical use today, such as mitoxantrone, are not included in this table. FDA pregnancy risk categories B 
through X have been replaced by new risk classification; the older drug pregnancy risk designations are not included in this table.
b
May not be enough published data to make final conclusions.
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Table 3
US MEC, US SPR, and QFP provider tools.a
Provider tool Description
US MEC, US SPR, QFP Print versions of the guidance documents
US MEC/US SPR app An easy to use reference that combines information from both the US MEC and US SPR that features a streamlined 
interface so providers can access the guidance quickly and easily (available for iOS and Android operating systems)
QFP app An easy to use reference to help providers make the best use of every family planning visit by streamlining 
decisions on what services to offer and how to provide them (available for iOS and Android operating systems)
US MEC Wheel An easy to use tool similar to a pregnancy gestation wheel that summarizes US MEC classifications; the medical 
conditions and personal characteristics are around the outside of the wheel, the contraceptive methods around the 
inside of the wheel, and the recommendations are revealed as the wheel turns
US MEC Summary 
Chart
A color-coded summary chart of US MEC classifications for IUDs, implants, DMPA, POPs, and CHCs
US SPR Charts Three charts are available that cover two main topics each including:
1 when to start using specific contraceptive methods and routine follow-up after contraceptive 
initiation;
2 recommended actions after late or missed combined oral contraceptives, delayed application or 
detachment with combined hormonal patch, and delayed insertion or reinsertion with combined 
vaginal ring;
3 management of the IUD when an IUD user is found to have pelvic inflammatory disease and 
management of women with bleeding irregularities while using contraception
Effectiveness of Family 
Planning Methods Chart
A chart that lists family planning methods by level of effectiveness during typical use from most to least effective
US MEC: US Medical Eligibility Criteria for Contraceptive Use; US SPR: US Selected Practice Recommendations for Contraceptive Use; QFP: 
Quality Family Planning Services; IUD: intrauterine devices; DMPA: depot medroxyprogesterone acetate; POPs: progestin-only pills; CHCs: 
combined hormonal contraceptives.
aAvailable at http://www.cdc.gov/reproductivehealth/contraception/contraception_guidance.htm
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